<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did EPIX's R&amp;D expenses trend impact Q1 2025 profits?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/8/2025 09:40pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">In Q1 2025, EPIX's R&amp;D expenses decreased to $3.5 million, down from $6.2 million in the same period of the previous year, contributing to a reported net loss of $6.4 million for the quarter, improved from a $9.0 million net loss in Q1 2024.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:F,comeFrom:"AInvestShareLink",events:[],answerSource:k}],fetch:{},error:l,state:{sharePreviewModule:{loadJgySuccess:m,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:k,cache_builder:a,reply_action:"Answer",execute_mode:v,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did EPIX's R&D expenses trend impact Q1 2025 profits?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did EPIX's R&D expenses trend impact Q1 2025 profits?\",\"user_id\":\"dp12168598\",\"user_name\":\"\",\"trace_id\":\"aa1f8f05-07a1-405a-86f6-4aa2cc35e49f\",\"session_id\":\"aa1f8f05-07a1-405a-86f6-4aa2cc35e49f\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:G,title:H,summary:I,full_summary:"Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock. ESSA Pharma Inc. (EPIX) is a clinical-stage biotechnology company that pioneered research into novel prostate cancer therapies targeting androgen receptor signaling. This page provides investors and industry observers with timely updates on corporate developments, including strategic reviews and historical clinical trial data. Access verified press releases, financial filings, and official statements related to EPIX's discontinued clinical programs and ongoing business evaluations. Our curated news collection ensures efficient tracking of key milestones in the company's transition from active drug development to strategic repositioning. Content includes updates on partnership opportunities, regulatory communications, and analyses of EPIX's specialized approach to oncology research. Bookmark this page for direct access to primary source materials and unfiltered corporate announcements, maintained for both professional investors and research stakeholders. 05\u002F08\u002F2025 07:00 AM News ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025 Rhea-AI Summary ESSA Pharma (NASDAQ: EPIX) reported its fiscal Q2 2025 financial results, highlighting ongoing efforts to evaluate strategic options after discontinuing its prostate cancer clinical trials. The company recorded a net loss of $6.4 million, improved from $9.0 million in Q2 2024. R&D expenses decreased to $3.5 million from $6.2 million, while G&A expenses reduced to $3.9 million from $4.3 million year-over-year. The company maintains a strong financial position with $113.9 million in cash and short-term investments and $113.5 million in net working capital as of March 31, 2025. ESSA is exploring various strategic alternatives, including potential mergers, acquisitions, or business combinations, while implementing cost reductions and ",url:J,image_url:a,video_url:a,publish_time:K,search_extra_info:{search_burial_info:{id:n,uid:n,ab:{scene_id:L,layer_exp:[{layer_id:M,exp_id:N}]}}},simhash:"e6cd1599abd62a96",msg_id:n}}],answer_chain_name:O,agent_mode:P,native_answer:a,come_from:a,text_answer:F,trace_id:e,cost:22622,event_names:a,question:d,fallback_type:Q,input_type:R,fall_back_reason:{fall_back_type:Q,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:e,first_return_cost:3630,cache_type:"no_cache",question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:w,remote_svc:k,slots:[],answer_type:v,user_id:s,skill_name:x},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:s,question:d,source:k,raw_question:d,version:"3.4.1",action_name:x,nlu:{entity:[{type:S,value:"EPIX.O",market:T}]},output_time:w,deep_research:c,deep_thinking:c,agent_mode:P},extra:{}},{answer_path:g,section:{id:h,info_texts:["Thinking"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:g,section:{id:h,info_texts:["Querying Stock: EPIX R&D Expenses, Net Income in Q1 2025"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:y},logs:[],extra:{action:"Querying Stock",action_input:"EPIX R&D Expenses, Net Income in Q1 2025",thought:U}},{answer_path:g,section:{id:h,info_texts:["Searching Web: Impact of R&D expenses on EPIX's profit"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:y},logs:[],extra:{action:"Searching Web",action_input:V,thought:U}},{answer_path:f,section:{id:z,info_texts:[],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:h,info_texts:["Calculating: Impact of R&D expenses on EPIX's profit"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:y},logs:[],extra:{action:"Calculating",action_input:V,thought:"I can't get the R&D expenses and Q1 2025 net income of EPIX by FinQuery, and the impact of R&D expenses on EPIX's profit by Search. I will change my plan to use Calculator to calculate the impact of R&D expenses on EPIX's profit."}},{answer_path:f,section:{id:z,info_texts:[],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:z,info_texts:[],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:h,info_texts:["Generating Answer"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:A,info_texts:[],show_type:B,voice_txt:"In",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:2000,info_texts:[],show_type:B,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:J,image_url:a,video_url:a,title:H,summary:I,index:G,publish_time:K,search_id:n,search_uid:n,search_ab:{scene_id:L,layer_exp:[{layer_id:M,exp_id:N}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:A,info_texts:[],show_type:B,voice_txt:C,text_answer:C,rich_text:C,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:f,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:X,market_id:T,name:"ESSA Pharma",domain:S},pos:12,section_id:A,txt:X,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:h,info_texts:["Completed"],show_type:i,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:o,query_text:o,trace_info:{item_id:"e6ad99a0babaf84094b33f0bef2dec39",item_type:j,item_name:o,rec_info:Y}},{display_text:p,query_text:p,trace_info:{item_id:"880a1ee15f7b891b39342441a937af42",item_type:j,item_name:p,rec_info:Z}},{display_text:q,query_text:q,trace_info:{item_id:"7f2952f17302b4e58d8d8eb5a11a31ae",item_type:j,item_name:q,rec_info:_}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:m,type:"1",display2:c,url:a}},request_config:[{source_type:$,related_name:aa}],puuid:D,tag:a,category:"custom",uuid:ab}],global:{urp_static_data:[{name:aa,value:{status_code:m,columns:[{type:r,index_name:ac,key:ac},{type:r,index_name:ad,key:ad},{type:r,index_name:ae,key:ae},{type:r,index_name:af,key:af},{type:r,index_name:ag,key:ag}],datas:[{send_text:o,item_type:j,rec_info:Y,display_text:o,rec_reason:a},{send_text:p,item_type:j,rec_info:Z,display_text:p,rec_reason:a},{send_text:q,item_type:j,rec_info:_,display_text:q,rec_reason:a}],dataSize:$,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ah,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:u,"min-height":"100%",position:ai,height:u},isMaterial:c,id:ah,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:m,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:E,componentUuid:ab,script:[{name:aj,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:E,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:E},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:u,position:ai,height:u},isMaterial:b,_id:19,id:aj,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:ak,voice_txt:a,tracking_info:{},uuid:D},order:{is_auto:c,render_for:ak,chart_type:"command",puuid:D}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:t,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:x,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:v,answer_chain_name:O},is_deep_research:c,deep_thinking:c,create_time:1746711670767},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:l,docsData:[],quoteData:l},tplType:"question"},events:al,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:al,client_ip:a,question:d,user_id:s,user_name:a,trace_id:e,session_id:e,source:k,input_type:R}}],userId:s,userName:a,startTime:w,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:l,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:m,traceTableData:l,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-epixs-rd-expenses-trend-impact-q1-2025-profits-c10d7c\u002F",config:{_app:{basePath:am,assetsPath:am,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"How did EPIX's R&D expenses trend impact Q1 2025 profits?","aa1f8f05-07a1-405a-86f6-4aa2cc35e49f","other\u002FopenAnswer","progress\u002Fsearching_for",1000,"searching_for","llm_generated","ths_ainvest_lite_web",null,0,"802a6b6d99b2f597","What was EPIX's R&D expense in Q1 2025?","What was EPIX's profit margin in Q1 2025?","How did analysts adjust their earnings estimates for EPIX post-Q1 2025?","STR","dp12168598","signal","auto","agent",1746711648145,"explain news events","thinking",999,2001,"rich_text",".","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","In Q1 2025, EPIX's R&D expenses decreased to $3.5 million, down from $6.2 million in the same period of the previous year, contributing to a reported net loss of $6.4 million for the quarter, improved from a $9.0 million net loss in Q1 2024.",4,"Essa Pharma Stock Price, News & Analysis","Key findings include:.- 88% of patients achieved PSA90.- 69% achieved PSA90 in less than 90 days.- 63% achieved PSA \u003C0.2ng\u002FmL.- After 15.2 months, median time to PSA progression and radiographic progression-free survival not yet reached.- Combination well-tolerated with durable PSA reductions.- Phas...","https:\u002F\u002Fwww.stocktitan.net\u002Fnews\u002FEPIX\u002F","2025-05-08","oeqxkhszf","oeqxkhszf_layer","mix_en_config_hybrid_summary","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","186","The user wants to analyze how EPIX's R&D expenses impacted its Q1 2025 profits. I should focus on the R&D expenses and Q1 2025 net profit data and market analyses of the impact of R&D expenses on profits. I will use FinQuery for the data; use Search for the analysis in the market.","Impact of R&D expenses on EPIX's profit","In Q1 2025, EPIX's R&D expenses decreased to $3.5 million, down from $6.2 million in the same period of the previous year, contributing to a reported net loss of $6.4 million for the quarter, improved from a $9.0 million net loss in Q1 2024[^4]","EPIX","2+679_496_21_554+0+0+aa1f8f05-07a1-405a-86f6-4aa2cc35e49f+e6ad99a0babaf84094b33f0bef2dec39+llm_generated+aimeTagAnalysis+0+0.026085659861564636+1","2+679_496_21_554+0+0+aa1f8f05-07a1-405a-86f6-4aa2cc35e49f+880a1ee15f7b891b39342441a937af42+llm_generated+aimeTagAnalysis+0+0.022986728698015213+2","2+679_496_21_554+0+0+aa1f8f05-07a1-405a-86f6-4aa2cc35e49f+7f2952f17302b4e58d8d8eb5a11a31ae+llm_generated+aimeTagAnalysis+0+0.009159170091152191+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>